Savara has $146M liquidity but CMC RTF delays BLA; resubmission planned for Dec 2025

Company: Savara Inc. (NYSE: MSTX) - quick, plain-language read on what's happening inside and what the income statement shows.

Snapshot - facts from the 10-Q (period ended June 30, 2025):
- Cash and cash equivalents: $17,436,000.
- Short-term investments: $129,007,000.
- Cash + short-term investments: $146,443,000.
- Total assets: $163,765,000; total liabilities: $43,281,000; stockholders' equity: $120,484,000.
- Long-term debt (carrying value): $29,653,000 (Hercules term loan; maturity April 1, 2030).
- Accumulated deficit: $(546,290,000).
- Shares outstanding (as of Aug 13, 2025): 172,836,922; weighted-average shares (6 months): 216,289,923.
- Net loss - three months ended Jun 30, 2025: $(30,401,000) (EPS basic & diluted: $(0.14)).
- Net loss - six months ended Jun 30, 2025: $(57,040,000) (EPS: $(0.26)).
- R&D expense (Q2 2025): $20,751,000; General & Administrative (Q2 2025): $10,655,000; Total operating expenses (Q2 2025): $31,440,000.
- Cash used in operating activities (six months): $(53,450,000).
- Company states cash + short-term investments are "sufficient to fund the Company's operations for at least the next twelve months."

What's happening inside - the operational story
- The company is a clinical-stage biopharma focused on MOLBREEVI (molgramostim) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). Development and regulatory work are the core activities - no product revenue to date.
- Regulatory setback: the FDA issued a Refusal to File (RTF) for the BLA in May 2025 citing incomplete Chemistry, Manufacturing & Controls (CMC) information. Management says the RTF was not due to safety or efficacy and plans to resubmit the BLA in December 2025 with a Priority Review request.
- Financing and liquidity moves: closed an initial $30M draw under a Hercules term loan (facility up to $200M, further tranches contingent on milestones including FDA approval and revenue). Initial draw repaid the prior SVB loan. The term loan includes restrictive covenants (cash-collateral requirements tied to outstanding principal, conditional revenue covenants if >$50M drawn) and relatively high floating interest (prime-based, ~8.95% at 6/30/25 reported).
- Development spending is rising as the company spends on CMC, an additional drug substance manufacturer, regulatory affairs, and pre-commercial activities.

Income statement - positives
- Strong liquidity mix: $146.4M in cash and short-term investments provides a meaningful buffer and management explicitly states it should cover at least 12 months of operations from the filing date.
- RTF not related to safety or efficacy; the company has a clear path (CMC info) and a fixed resubmission target (Dec 2025) - a defined near-term clinical/regulatory catalyst.
- Interest income and modest other income partially offset losses (other income, net was $2.8M for six months). Management reduced prior SVB exposure and secured a committed lender (Hercules) for staged funding tied to milestones.

Income statement - negatives / risks
- Losses widening: net loss increased to $57.0M for the first half of 2025 vs $42.6M a year earlier - driven by higher R&D (+$5.5M YoY) and G&A (+$8.7M YoY). Operating cash burn remains high (~$53.5M in six months).
- Heavy reliance on milestone-conditioned debt and potential future equity - the Hercules facility tranches beyond the initial draw are largely conditioned on FDA approval and revenue milestones, meaning additional cash is not certain until regulatory/commercial events occur.
- Debt covenants and cash-collateral rules (50% of outstanding principal, rising to 70% until approval in some cases) increase liquidity constraints and could hamper flexibility.
- Regulatory execution risk remains front-and-center: RTF for CMC means resubmission must satisfy FDA expectations; delays or additional FDA requests could push costs and extend cash needs.
- Dilution risk: large block of reserved shares, warrants and equity awards (total shares reserved ~60.9M as of 6/30/25) and prior equity raises; management states it may need to raise capital via equity, debt, or deals.
- Accumulated deficit is significant (~$546M), underscoring long history of losses and need for future financing until product revenue (if any) materializes.

Key upcoming catalysts and what to watch
- BLA resubmission targeted for December 2025 and request for Priority Review - the primary near-term value catalyst; success unlocks additional Hercules tranches and reduces financing risk.
- Cash burn / monthly cash runway updates - watch quarterly cash used in operations and whether management tightens spending or raises capital.
- Any additional FDA feedback after resubmission (requests for more data or on-site inspections tied to CMC).
- Draws under the Hercules facility and compliance with its covenants (cash control account %, Conditional Minimum Revenue Covenant if >$50M drawn).
- Manufacturing milestones and payments (FujiFilm, GEMA, PARI) and progress on establishing the second drug-substance manufacturer.

Bottom line - straight take
Savara is a development-stage biotech with a defined regulatory path (BLA resubmission due Dec 2025) but still burning cash at a high rate. The balance sheet shows a healthy short-term investment cushion ($146.4M total liquidity) that management says funds >12 months, but near-term financing flexibility is constrained by a milestone-driven term loan with strict covenants and by the fact that future draws are conditional on approval/revenue outcomes. The RTF is a material but fixable setback (CMC-related, not safety/efficacy). Investors should focus on the quality/timeliness of the BLA resubmission, cash burn trends, and any capital raises or loan tranche draws that follow regulatory progress.

If you want, I can produce a two-quarter comparison table of the P&L line-items and a short timeline of the next 6-12 months (regulatory and financing milestones).